İlaçlar ve Gelişmekte Olan Sinir Sistemi
Özet
Gebelik sırasında maruz kalınan çeşitli ilaç ve maddelerin, fetüsün gelişmekte olan sinir sistemi üzerinde doğrudan veya dolaylı teratojenik, nörogelişimsel ve nörodavranışsal ciddi etkileri bulunmaktadır. Alkol, antiepileptikler, opioidler ve diğer psikoaktif maddelerin fetal beyin gelişimi, beslenme ve kan akışı üzerindeki zararları; yapısal anomalilerden uzun vadeli bilişsel yetersizliklere kadar uzanan geniş bir klinik tabloya yol açmaktadır. Maternal genetik yatkınlık ve çevresel faktörlerle karmaşıklaşan bu süreçte, gebelik boyunca bilinçli ilaç kullanımı ve koruyucu önlemlerin alınması fetal sağlığın korunması için kritik öneme sahiptir.
Prenatal exposure to various medications and substances poses significant risks to the developing fetal nervous system, leading to structural, neurological, and neurobehavioral impairments. Alcohol, antiepileptics, opioids, and other psychoactive drugs disrupt fetal brain development, blood flow, and nutrition, resulting in a wide spectrum of clinical consequences ranging from congenital malformations to long-term cognitive deficits. Given the complex interplay of maternal genetics and environmental factors, prioritizing clinical management and cautious medication selection during pregnancy is essential for protecting fetal health.
Referanslar
Kesserwani H. Death and Rebirth of the Thalidomide Molecule: A Case of Thalidomide-Induced Sensory Neuropathy. Cureus. 2021;13:e13140.
Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology. 2015;40:61-87.
Woodward LJ, McPherson CC, Volpe JJ. Passive Addiction and Teratogenic Effects. Joseph J Volpe (ed). Volpe's Neurology of the Newborn. Sixth edition. Philadelphia, PA: Elsevier, 2018. p. 1149-1189.
Vernadakis A, Parker KK. Drugs and the developing central nervous system. Pharmacol Ther. 1980;11(3):593-647.
De Giovanni N, Marchetti D. Cocaine and its metabolites in the placenta: a systematic review of the literature. Reprod Toxicol. 2012;33:1-14.
Dodge NC, Jacobson JL, Jacobson SW. Protective effects of the alcohol dehydrogenase-ADH1B*3 allele on attention and behavior problems in adolescents exposed to alcohol during pregnancy. Neurotoxicol Teratol. 2014;41:43-50.
Vassoler FM, Byrnes EM, Pierce RC. The impact of exposure to addictive drugs on future generations: Physiological and behavioral effects. Neuropharmacology. 2014;76:269-275.
Mutluer T, Bozkurt H, Coşkun M, Zoroğlu SS. Fetal alkol spektrum bozuklukları: güncel bir derleme. Çocuk ve Gençlik Ruh Sağlığı Dergisi. 2013;20:47-56.
Lemoine P, Harrousseau H, Borteyru JP. Les enfants de parents alcooliques. Anomalies observees. A propos de 127 cas. Quest Med. 1968;25:477.
Akison LK, Moritz KM, Reid N. Adverse reproductive outcomes associated with fetal alcohol exposure: a systematic review. Reproduction. 2019;157:329-343.
May PA, Baete A, Russo J, Elliott AJ, et al. Prevalence and characteristics of fetal alcohol spectrum disorders. Pediatrics. 2014;134:855-866.
Hoyme HE, Kalberg WO, Elliott AJ, Blankenship J, et al. Updated clinical guidelines for diagnosing fetal alcohol spectrum disorders. Pediatrics. 2016;138:e20154256.
Wozniak JR, Riley EP, Charness ME. Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder. Lancet Neurol. 2019;18:760-770.
Norman AL, Crocker N, Mattson SN, Riley EP. Neuroimaging and fetal alcohol spectrum disorders. Dev Disabil Res Rev. 2009;15:209-17.
Lee RD, An SM, Kim SS, Rhee GS, Kwack SJ, Seok JH, et al. Neurotoxic effects of alcohol and acetaldehyde during embryonic development. J Toxicol Environ Health A. 2005;68:2147-2162.
Ramadoss J, Magness RR. Vascular effects of maternal alcohol consumption. Am J Physiol Heart Circ Physiol. 2012;303:H414-H421.
May PA, Hamrick KJ, Corbin KD, Hasken JM, Marais AS, Blankenship J, Hoyme HE, Gossage JP. Maternal nutritional status as a contributing factor for the risk of fetal alcohol spectrum disorders. Reprod Toxicol. 2016;59:101-108.
Young JK, Giesbrecht HE, Eskin MN, Aliani M, Suh M. Nutrition implications for fetal alcohol spectrum disorder. Adv Nutr. 2014;5:675-692.
Bonthius DJ Jr, Winters Z, Karacay B, Bousquet SL, Bonthius DJ. Importance of genetics in fetal alcohol effects: null mutation of the nNOS gene worsens alcohol-induced cerebellar neuronal losses and behavioral deficits. Neurotoxicology. 2015;46:60-72.
Miller-Pinsler L, Pinto DJ, Wells PG. Oxidative DNA damage in the in utero initiation of postnatal neurodevelopmental deficits by normal fetal and ethanol-enhanced oxidative stress in oxoguanine glycosylase 1 knockout mice. Free Radic Biol Med. 2015;78:23-29.
Noel M, Norris EH, Strickland S. Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice. Proc Natl Acad Sci USA. 2011;108:5069-5074.
Heaton MB, Paiva M, Madorsky I, Siler-Marsiglio K, Shaw G. Effect of bax deletion on ethanol sensitivity in the neonatal rat cerebellum. J Neurobiol. 2006;66:95-101.
Ismail S, Buckley S, Budacki R, Jabbar A, Gallicano GI. Screening, diagnosing and prevention of fetal alcohol syndrome: is this syndrome treatable? Dev Neurosci. 2010;32:91-100.
Sarmah S, Marrs JA. Complex cardiac defects after ethanol exposure during discrete cardiogenic events in zebrafish: prevention with folic acid. Dev Dyn. 2013;242:1184-1201.
Otero NK, Thomas JD, Saski CA, Xia X, et al. Choline supplementation and DNA methylation in the hippocampus and prefrontal cortex of rats exposed to alcohol during development. Alcohol Clin Exp Res. 2012;36:1701-1709.
Miller GW, Labut EM, Lebold KM, Floeter A, Tanguay RL, Traber MG. Zebrafish (Danio rerio) fed vitamin E-deficient diets produce embryos with increased morphologic abnormalities and mortality. J Nutr Biochem. 2012;23:478-486.
Ryan SH, Williams JK, Thomas JD. Choline supplementation attenuates learning deficits associated with neonatal alcohol exposure in the rat: effects of varying the timing of choline administration. Brain Res. 2008;1237:91-100.
Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132-1138.
Holmes LB, Hernandez-Diaz S. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol. 2012;94:599-606.
Danielsson BR, Lansdell K, Patmore L, Tomson T. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res. 2003;55:147-157.
Harden CL, Pennell PB, Koppel BS, et al; American Academy of Neurology; American Epilepsy Society. Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:142-149.
Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA. 2002;99:15089-15094.
Morte MI, Carreira BP, Falcao MJ, et al. Evaluation of neurotoxic and neuroprotective pathways affected by antiepileptic drugs in cultured hippocampal neurons. Toxicol In Vitro. 2013;27:2193-2202.
Sankar R, Lerner JT. Teratogenicity of antiepileptic drugs: role of pharmacogenomics. Int Rev Neurobiol. 2008;83:215-225.
Hill DS, Wlodarczyk BJ, Palacios AM, Finnell RH. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother. 2010;10:943-959.
Lopez-Garcia MA, Feria-Romero IA, Fernando-Serrano H, Escalante-Santiago D, Grijalva I, Orozco-Suarez S. Genetic polymorphisms associated with antiepileptic metabolism. Front Biosci (Elite Ed). 2014 ;6:377-386.
Azarbayjani F, Borg LA, Danielsson BR. Increased susceptibility to phenytoin teratogenicity: excessive generation of reactive oxygen species or impaired antioxidant defense? Basic Clin Pharmacol Toxicol. 2006;99:305-311.
Voinescu PE, Pennell PB. Management of epilepsy during pregnancy. Expert Rev Neurother. 2015;15:1171-1187.
Gedzelman E, Meador KJ. Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv Drug Saf. 2012;3:71-87.
Lowe CR. Congenital malformations among infants born to epileptic women. Lancet. 1973;1:9-10.
Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure. 2015;28:46-50.
Desmond MM, Schwanecke RP, Wilson GS, Yasunaga S, Burgdorff I. Maternal barbiturate utilization and neonatal withdrawal symptomatology. J Pediatr. 1972;80:190-197.
Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal gabapentin withdrawal syndrome. Pediatr Neurol. 2015;53: 445-447.
Hey E. Effect of maternal anticonvulsant treatment on neonatal blood coagulation. Arch Dis Child Fetal Neonatal Ed. 1999;81:F208-F210.
Inoyama K, Meador KJ. Cognitive outcomes of prenatal antiepileptic drug exposure. Epilepsy Res. 2015;114:89-97.
Deshmukh U, Adams J, Macklin EA, et al. Behavioral outcomes in children exposed prenatally to lamotrigine, valproate, or carbamazepine. Neurotoxicol Teratol. 2016;54:5-14.
Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696-1703.
Harden CL, Pennell PB, Koppel BS,et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73:142-149.
Smid MC, Metz TD, Gordon AJ. Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. Clin Obstet Gynecol. 2019;62:168-184.
Gouin K, Murphy K, Shah PS; Knowledge Synthesis group on Determinants of Low Birth Weight and Preterm Births. Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. Am J Obstet Gynecol. 2011;204:340.e1-12.
Scott-Goodwin AC, Puerto M, Moreno I. Toxic effects of prenatal exposure to alcohol, tobacco and other drugs. Reprod Toxicol. 2016;61:120-30.
Cain MA, Bornick P, Whiteman V. The maternal, fetal, and neonatal effects of cocaine exposure in pregnancy. Clin Obstet Gynecol. 2013;56:124-132.
Strathearn L, Mayes LC. Cocaine addiction in mothers: potential effects on maternal care and infant development. Ann N Y Acad Sci. 2010;1187:172-183.
Schempf AH. Illicit drug use and neonatal outcomes: a critical review. Obstet Gynecol Surv. 2007;62:749-57.
Mayes LC. Developing brain and in utero cocaine exposure: effects on neural ontogeny. Dev Psychopathol. 1999;11:685-714.
Dinger J, Hinner P, Reichert J, Rüdiger M. Methamphetamine Consumption during Pregnancy - Effects on Child Health. Pharmacopsychiatry. 2017;50:107-113.
Jablonski SA, Williams MT, Vorhees CV. Mechanisms involved in the neurotoxic and cognitive effects of developmental methamphetamine exposure. Birth Defects Res C Embryo Today. 2016;108:131-141.
Schiller C, Allen PJ. Follow-up of infants prenatally exposed to cocaine. Pediatr Nurs. 2005;31:427-436.
Keller RW Jr, Snyder-Keller A. Prenatal cocaine exposure. Ann N Y Acad Sci. 2000;909:217-232.
Jablonski SA, Williams MT, Vorhees CV. Neurobehavioral Effects from Developmental Methamphetamine Exposure. Curr Top Behav Neurosci. 2016;29:183-230.
Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25:139-151.
Jones HE, O’Grady KE, Malfi D, Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2008;17:372-386.
Finnegan LP. Effects of maternal opiate abuse on the newborn. Fed Proc. 1985;44:2314-2317.
Rahbar F. Observations on methadone withdrawal in 16 neonates. Clin Pediatr (Phila). 1975;14:369-371.
Ostrea EM Jr, Chavez CJ, Strauss ME. A study of factors that influence the severity of neonatal narcotic withdrawal. J Pediatr. 1976;88:642-645.
Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone-maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol. 1984;6:271-275.
Lifschitz MH, Wilson GS, Smith EO, Desmond MM. Fetal and postnatal growth of children born to narcotic-dependent women. J Pediatr. 1983;102:686-691.
Hammer RP Jr, Ricalde AA, Seatriz JV. Effects of opiates on brain development. Neurotoxicology. 1989;10:475-483.
Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69-78.
Elkomy MH, Sultan P, Carvalho B, et al. Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. Clin Pharmacol Ther. 2015;97:167-176.
Hudak ML, Tan RC, Committee on Drugs, Committee on Fetus and Newborn, et al. Neonatal drug withdrawal. Pediatrics. 2012;129:e540-e560.
Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev. 2010;(10):CD002059.
Wiles JR, Isemann B, Ward LP, Vinks AA, et al. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr. 2014;165:440-446.
Tran H, Robb AS. SSRI use during pregnancy. Semin Perinatol. 2015;39:545-547.
Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436-443.
Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014;10:369-392.
Grigoriadis S, VonderPorten EH, Mamisashvili L, Eady A, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74:e309-e320.
Johnson KC, Smith AK, Stowe ZN, et al. Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: differences in language and behavior, but not cognitive function. J Clin Psychiatry. 2016;77:e176-e182.
Knoppert DC, Nimkar R, Principi T, Yuen D. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit. 2006;28:5-7.
Sie SD, Wennink JM, van Driel JJ, et al. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed. 2012;97:F472-F476.
Wikner BN, Stiller CO, Kallen B, Asker C. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: maternal characteristics. Pharmacoepidemiol Drug Saf. 2007;16:988-994.
Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics. 1992;23:18-23.
Laegreid L, Hagberg G, Lundberg A. Neurodevelopment in late infancy after prenatal exposure to benzodiazepines—a prospective study. Neuropediatrics. 1992;23:60-67.
Mortensen JT, Olsen J, Larsen H, Bendsen J, et al. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol. 2003;18:769-771.
Van De Velde M, De Buck F. Anesthesia for nonobstetric surgery in the pregnant patient. Minerva Anestesiol. 2007;73:235-240.
Stratmann G. Review article: neurotoxicity of anesthetic drugs in the developing brain. Anesth Analg. 2011;113:1170-1179.
Palanisamy A. Maternal anesthesia and fetal neurodevelopment. Int J Obstet Anesth. 2012;21:152-162.
Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003;23:876-882.
Volkow ND, Compton WM, Wargo EM. The risks of marijuana use during pregnancy. JAMA. 2017;317:129-130.
Chabarria KC, Racusin DA, Antony KM, et al. Marijuana use and its effects in pregnancy. Am J Obstet Gynecol. 2016;215:506. e501-506.e507.
El Marroun H, Tiemeier H, Steegers EA, Roos-Hesselink JW, et al. A prospective study on intrauterine cannabis exposure and fetal blood flow. Early Hum Dev. 2010;86:231-236.
Warshak CR, Regan J, Moore B, Magner K, et al. Association between marijuana use and adverse obstetrical and neonatal outcomes. J Perinatol. 2015;35:991-995.
Conner SN, Bedell V, Lipsey K, Macones GA, et al. Maternal marijuana use and adverse neonatal outcomes: a systematic review and meta-analysis. Obstet Gynecol. 2016;128:713-723.
Gray KA, Day NL, Leech S, Richardson GA. Prenatal marijuana exposure: effect on child depressive symptoms at ten years of age. Neurotoxicol Teratol. 2005;27:439-448.
Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry. 2008;47:254-263.
